Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening

Urology

Volumn 64, Issue 2, 2004, Pages 317-322

  Oliver, Steven E ^a   Holly, Jeff ^b   Peters, Tim J ^b   Donovan, Jenny ^b   Persad, Raj ^b   Gillatt, David ^c   Pearce, Anya ^b   Hamdy, Freddie C ^d   Neal, David E ^e   Gunnell, David ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN DETERMINATION; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; COHORT STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 4143126841     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.03.018     Document Type: Article

References (21)

1. Selley S., Donovan J., Faulkner A., et al. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1:1997;1-96
2. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial. JAMA. 279:1998;1542-1547
3. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk a prospective study. Science. 279:1998;563-566
4. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate cancer risk a population-based, case-control study. J Natl Cancer Inst. 90:1998;911-915
5. Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 94:2002;1099-1106
6. Chokkalingam A.P., Pollak M., Fillmore C.-M., et al. Insulin-like growth factors and prostate cancer a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 10:2001;421-427
7. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk a prospective study. J Natl Cancer Inst. 92:2000;1910-1917
8. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:2000;1-9
9. Wolk A., Andersson S.-O., Mantzoros C.S., et al. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet. 356:2000;1902-1903
10. Djavan B., Bursa B., Seitz C., et al. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology. 54:1999;603-606
11. Ismail A.H., Pollak M., Behlouli H., et al. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol. 168:2002;2426-2430
12. Donovan J., Hamdy F., Neal D., et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 7:2003;1-88
13. Oliver S.E., Gunnell D., Donovan J., et al. Screen-detected prostate cancer and the insulin-like growth factor axis results of a population-based case-control study. Int J Cancer. 108:2004;887-892
14. Cheetham T.D., Holly J.M., Baxter R.C., et al. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol. 157:1998;81-87
15. Dorfman D.D., Alf E. Maximum likelihood estimation of signal detection theory and determination of confidence intervals-rating method data. J Math Psychol. 6:1969;487-496
16. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves a nonparametric approach. Biometrics. 44:1988;837-845
17. StataCorp. Stata Statistical Software: Release 7.0. 2001;Stata Corporation, College Station, Texas
18. Finne P., Auvinen A., Koistinen H., et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab. 85:2000;2744-2747
19. Khosravi J., Diamandi A., Mistry J., et al. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab. 86:2001;694-699
20. Cutting C.W.M., Hunt C., Nisbet J.A., et al. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 83:1999;996-999
21. Chokkalingam A.P., Gao Y.T., Deng J., et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate. 52:2002;98-105